Abstract
Background
Beta‐blockers exert complex effects on plasma N‐terminal‐pro‐B‐type natriuretic peptide (NT‐proBNP) level.
Hypothesis
We aimed to investigate whether NT‐proBNP was still able to mirror the severity of chronic heart failure and predict the prognosis of the disease after administration of a beta‐blocker.
Methods
Forty‐four patients with chronic congestive heart failure were enrolled in the study to randomly receive carvedilol or bisoprolol in addition to background therapy. These patients underwent clinical measurement and blood sampling for NT‐proBNP measurement at baseline and 3 or 7 months after the addition of the beta‐blocker. The patients were followed‐up for 3 years in order to register the occurrence of all‐cause death.
Results
NT‐proBNP level showed a positive correlation with the severity of heart failure as evaluated by New York Heart Association (NYHA) classification both before and after administration of either beta‐blocker. The relationship between NT‐proBNP and NYHA class was not weakened with the duration of therapy. Furthermore, NT‐proBNP was the only independent predictor of all‐cause mortality both before and after administration of either beta‐blocker. Left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), age, NYHA class and treatment group were not independently predictive of mortality in this study.
Conclusions
The ability of NT‐proBNP to reflect the severity and to predict the endpoint in chronic heart failure is not undermined after administration of a beta‐blocker, suggesting that NT‐proBNP remains a sensitive biomarker for chronic heart failure both before and after administration of a beta‐blocker. Copyright © 2007 Wiley Periodicals, Inc.
Keywords: natriuretic peptide, brain, heart failure, congestive, adrenergic beta‐antagonists
Full Text
The Full Text of this article is available as a PDF (259.4 KB).
References
- 1. Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577–585. [DOI] [PubMed] [Google Scholar]
- 2. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M: Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end‐diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825–832. [DOI] [PubMed] [Google Scholar]
- 3. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, et al.: Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐proBNP): a new marker of cardiac impairment. Clin Endocrinol 1997; 47: 287–296. [DOI] [PubMed] [Google Scholar]
- 4. Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA: The amino‐terminal portion of pro‐brain natriuretic peptide (pro‐BNP) circulates in human plasma. Biochem Biophys Res Commun 1995; 214: 1175–1183. [DOI] [PubMed] [Google Scholar]
- 5. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, et al.: Analytical performance and diagnostic accuracy of a fully‐automated electrochemiluminescent assay for the N‐terminal fragment of the pro‐peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 2004; 42: 37–44. [DOI] [PubMed] [Google Scholar]
- 6. Clerico A, Emdin M: Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004; 50: 33–50. [DOI] [PubMed] [Google Scholar]
- 7. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA: N‐terminal pro‐brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003; 24: 1735–1743. [DOI] [PubMed] [Google Scholar]
- 8. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, et al.: Plasma N‐terminal pro‐brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia‐New Zealand Heart Failure Group. J Am Coll Cardiol 2001; 37: 1781–1787. [DOI] [PubMed] [Google Scholar]
- 9. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls GA, et al.: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N‐BNP) concentrations. Lancet 2000; 355: 1126–1130. [DOI] [PubMed] [Google Scholar]
- 10. Tanaka M, Ishizaka Y, Ishiyama Y, Kato J, Kida O, et al.: Chronic effect of beta‐adrenoceptor blockade on plasma levels of brain natriuretic peptide during exercise in essential hypertension. Hypertens Res 1996; 19: 239–245. [DOI] [PubMed] [Google Scholar]
- 11. Sanderson JE, Chan WW, Hung YT, Chan SK, Shun IO, et al.: Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 1995; 7: 502–507. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Marie PY, Mertes PM, Hassan‐Sebbag N, de Talence N, Djaballah K, et al.: Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta‐blockers. J Am Coll Cardiol 2004; 43: 353–359. [DOI] [PubMed] [Google Scholar]
- 13. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, et al.: Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 2005; 23: 1083–1090. [DOI] [PubMed] [Google Scholar]
- 14. Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, et al.: Introduction of metoprolol increases plasma B‐type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006; 113: 977–985. [DOI] [PubMed] [Google Scholar]
- 15. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, et al.: NT‐proBNP in severe chronic heart filure: rationale, design and preliminary results of the COPERNICUS NT‐proBNP substudy. Eur J Heart Fail 2004; 6: 343–350. [DOI] [PubMed] [Google Scholar]
- 16. Jourdain P, Funck F, Willemard C, Bellorini M, Guillard N, et al.: BNP and betablocker therapy in chronic heart failure. Eur Heart J 2000; 21(suppl): 403, Abstract. [Google Scholar]
- 17. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–1355. [DOI] [PubMed] [Google Scholar]
- 18. MERIT‐HF Study Group : Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure(MERIT‐HF). Lancet 1999; 353: 2001–2007. [PubMed] [Google Scholar]
- 19. CIBIS‐II Investigators and Committees : The Cardiac Insufficiency Bisoprolol Study II(CIBIS‐II): a randomized trial. Lancet 1999; 353: 9–13. [PubMed] [Google Scholar]
- 20. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Riegger GA, et al.: Augmentation of the cardiac natriuretic peptides by beta‐receptor antagonism: evidence from a population‐based study. J Am Coll Cardiol 1998; 32: 1839–1844. [DOI] [PubMed] [Google Scholar]